Achieve Life Sciences, Inc. SEC filings ACHV
Achieve Life Sciences, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Apr 15, 2009. Its latest annual report, Form ARS, was filed on Jun 8, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 1, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Jun 8, 2026 | Jun 8, 2026 |
| PRE 14A | Preliminary proxy statement | May 29, 2026 | May 29, 2026 |
| DEF 14A | Proxy statement | Apr 28, 2025 | Apr 28, 2025 |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 5, 2024 |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 7, 2023 |
| PRE 14A | Preliminary proxy statement | Apr 18, 2023 | Jun 7, 2023 |
| DEF 14A | Proxy statement | Apr 21, 2022 | May 31, 2022 |
| DEF 14A | Proxy statement | Mar 30, 2021 | May 11, 2021 |
| DEF 14A | Proxy statement | Apr 2, 2020 | May 12, 2020 |
| PRE 14A | Preliminary proxy statement | Mar 19, 2020 | May 12, 2020 |
| DEF 14A | Proxy statement | Mar 28, 2019 | May 14, 2019 |
| DEF 14A | Proxy statement | Aug 16, 2018 | Sep 20, 2018 |
| PRE 14A | Preliminary proxy statement | Jul 31, 2018 | Sep 20, 2018 |
| DEF 14A | Proxy statement | Apr 19, 2018 | May 22, 2018 |
| PRE 14A | Preliminary proxy statement | Apr 4, 2018 | May 22, 2018 |
| DEF 14A | Proxy statement | Sep 21, 2017 | Oct 26, 2017 |
| PRE 14A | Preliminary proxy statement | Sep 1, 2017 | Oct 26, 2017 |
| PRE 14A | Preliminary proxy statement | Mar 31, 2016 | May 26, 2016 |
| DEF 14A | Proxy statement | Apr 16, 2015 | May 21, 2015 |
| PRE 14A | Preliminary proxy statement | Mar 25, 2015 | May 21, 2015 |
| DEF 14A | Proxy statement | Apr 24, 2014 | May 29, 2014 |
| DEF 14A | Proxy statement | Apr 22, 2013 | May 24, 2013 |
| PRE 14A | Preliminary proxy statement | Apr 3, 2013 | May 24, 2013 |
| DEF 14A | Proxy statement | Apr 26, 2012 | May 31, 2012 |
| DEF 14A | Proxy statement | Apr 21, 2011 | May 26, 2011 |
| DEF 14A | Proxy statement | Apr 19, 2010 | Jun 8, 2010 |
| PRE 14A | Preliminary proxy statement | Mar 26, 2010 | Jun 8, 2010 |
Showing 27 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- ACHV (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Seattle, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 949858
- Former names
- ONCOGENEX PHARMACEUTICALS, INC. (until Jul 31, 2017); SONUS PHARMACEUTICALS INC (until Aug 7, 2008)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.